The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: Results from a population-based cohort in Eastern Europe

Journal of Crohn's and Colitis

Volumn 7, Issue 5, 2013, Pages 385-391

  Lakatos, Peter L ^a   Lovasz, Barbara D ^a   David, Gyula ^b   Pandur, Tunde ^b   Erdelyi, Zsuzsanna ^b   Mester, Gabor ^c   Balogh, Mihaly ^c   Szipocs, Istvan ^d   Molnar, Csaba ^e   Komaromi, Erzsebet ^f   Golovics, Petra A ^a   Vegh, Zsuzsanna ^a   Mandel, Michael ^a   Horvath, Agnes ^b   Szathmari, Miklos ^a   Kiss, Lajos S ^a   Lakatos, Laszlo ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Csolnoky F Province Hospital   (Hungary)

^c Grof Eszterhazy Hospital   (Hungary)

^d Municipal Hospital   (Hungary)

^e Magyar Imre Hospital   (Hungary)

^f Dept of Gastroenterology Municipal Hospital ^*  (Hungary)

Author keywords

IBD; ; Incidence; ; Lymphoma; ; Standardized incidence ratio

Indexed keywords

AZATHIOPRINE; IMMUNOMODULATING AGENT;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; DISEASE COURSE; DRUG EXPOSURE; ENTERITIS; EUROPE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ULCERATIVE COLITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; HUNGARY; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84875626330     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.06.011     Document Type: Article

References (32)

1. Lakatos P.L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down?. World J Gastroenterol 2006, 12:6102-6108.
2. Lakatos L., Kiss L.S., David G., Pandur T., Erdelyi Z., Mester G., et al. Incidence, disease phenotype at diagnosis and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis 2011, 17:2558-2565.
3. Lakatos P.L., Golovics P.A., David G., Pandur T., Erdelyi Z., Horvath A., et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from western Hungary between 1977-2009. Am J Gastroenterol 2012, 107:579-588.
4. Lakatos P.L., David G., Pandur T., Erdelyi Z., Mester G., Balogh M., et al. Risk of colorectal cancer and small bowel adenocarcinoma in Crohn's disease: a population-based study from western Hungary 1977-2008. J Crohns Colitis 2011, 5:122-128.
5. van Schaik F.D., van Oijen M.G., Smeets H.M., van der Heijden G.J., Siersema P.D., Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012, 61:235-240.
6. Alexander D.D., Mink P.J., Adami H.O., Chang E.T., Cole P., Mandel J.S., et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007, 120(Suppl. 12):1-39.
7. Baecklund E., Iliadou A., Askling J., Ekbom A., Backlin C., Granath F., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54:692-701.
8. Silman A.J., Petrie J., Hazleman B., Evans S.J. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20year follow up study. Ann Rheum Dis 1988, 47:988-992.
9. Peyrin-Biroulet L., Ferrante M., Magro F., Campbell S., Franchimont D., Fidder H., et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011, 5:477-483.
10. Wilkinson A.H., Smith J.L., Hunsicker L.G., Tobacman J., Kapelanski D.P., Johnson M., et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989, 47:293-296.
11. Lewis J.D., Bilker W.B., Brensinger C., Deren J.J., Vaughn D.J., Strom B.L. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001, 121:1080-1087.
12. Ekbom A., Helmick C., Zack M., Adami H.O. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991, 67:2015-2019.
13. Loftus E.V., Tremaine W.J., Habermann T.M., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000, 95:2308-2312.
14. Persson P.G., Karlen P., Bernell O., Leijonmarck C.E., Brostrom O., Ahlbom A., et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994, 107:1675-1679.
15. Askling J., Brandt L., Lapidus A., Karlen P., Bjorkholm M., Lofberg R., et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005, 54:617-622.
16. Bernstein C.N., Blanchard J.F., Kliewer E., Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91:854-862.
17. Kandiel A., Fraser A.G., Korelitz B.I., Brensinger C., Lewis J.D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-1125.
18. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lémann M., Cosnes J., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
19. Sokol H., Beaugerie L., Maynadié M., Laharie D., Dupas J.L., Flourié B., et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis Jan. 23 2012, [Epub ahead of print]. 10.1002/ibd.22889.
20. Farrell R.J., Ang Y., Kileen P., O'Briain D.S., Kelleher D., Keeling P.W., et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000, 47:514-519.
21. Siegel C.A., Marden S.M., Persing S.M., Larson R.J., Sands B. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
22. Otto S., Kasler M. Trends in cancer mortality and morbidity in Hungarian and international statistics. Characteristics and potential outcome of public health screening programs. Magy Onkol 2005, 49:99-101.
23. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24(Suppl. 170):2-6.
24. van Assche G., Dignass A., Panes J., Beaugerie L., Karagiannis J., Allez M., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
25. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl. A):5-36.
26. Herrinton L.J., Liu L., Weng X., Lewis J.D., Hutfless S., Allison J.E. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011, 106:2146-2153.
27. Reijasse D., Le Pendeven C., Cosnes J., Dehee A., Gendre J.P., Nicolas J.C., et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 2004, 10:85-90.
28. Copie-Bergman C., Niedobitek G., Mangham D.C., Selves J., Baloch K., Diss T.C., et al. Epstein-Barr virus in B-cell lymphomas associated with chronic suppurative inflammation. J Pathol 1997, 183:287-292.
29. Knosel T., Schewe C., Petersen N., Dietel M., Petersen I. Prevalence of infectious pathogens in Crohn's disease. Pathol Res Pract 2009, 205:223-230.
30. Wong N.A., Herbst H., Herrmann K., Kirchner T., Krajewski A.S., Moorghen M., et al. Epstein-Barr virus infection in colorectal neoplasms associated with inflammatory bowel disease: detection of the virus in lymphomas but not in adenocarcinomas. J Pathol 2003, 201:312-318.
31. Dayharsh G.A., Loftus E.V., Sandborn W.J., Tremaine W.J., Zinsmeister A.R., Witzig T.E., et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002, 122:72-77.
32. Vos A.C., Bakkal N., Minnee R.C., Casparie M.K., de Jong D.J., Dijkstra G., et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 2011, 17:1837-1845.